Subject
Cardiology and Cardiovascular Medicine,Nutrition and Dietetics,Endocrinology, Diabetes and Metabolism,Internal Medicine
Reference20 articles.
1. Tirzépatide : les leçons du programme Clinique SURPASS;Bordier;Med Mal Metab,2023
2. Sustainability of HbA1c control of tirzepatide vs. insulin glargine in people with type 2 diabetes and increased cardiovascular risk (SURPASS-4);Pearson;Diabetes,2022
3. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial;Rosenstock;Lancet,2021
4. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes;Frías;N Engl J Med,2021
5. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial;Ludvik;Lancet,2021